Inventor · disambiguated record
Alan Shuldiner
Also filed as: SHULDINER ALAN · SHULDINER ALAN R
19 granted patents·15 pending applications·66 citations·filing 1995–2025
92Inventor score
Top patents by PatentIndex Score
34 records- 0195US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 0294US10787647B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·10 cites·52 claims
- 0392US11753628B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·1 cites·26 claims
- 0488US11713461B2Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitorsREGENERON PHARMA·Filed 2020·Granted Aug 1, 2023·2 cites·15 claims
- 0586US2024141305A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0684US11845963B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 19, 2023·1 cites·12 claims
- 0784US11485958B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·1 cites·40 claims
- 0880US7312197B2Method of modifying glucose activity using polypeptides selectively expressed in fat tissueUNIV MARYLAND·Filed 2004·Granted Dec 25, 2007·16 cites·19 claims
- 0980US2023031669A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1076US12509687B2Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitorsREGENERON PHARMA·Filed 2023·Granted Dec 30, 2025·0 cites·13 claims
- 1176US2025333737A117ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1273US7550435B2Method of modifying glucose activity using polypeptides selectively expressed in fat tissueUNIV MARYLAND·Filed 2007·Granted Jun 23, 2009·2 cites·20 claims
- 1370US12359201B217ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 15, 2025·0 cites·39 claims
- 1467US2023263821A1Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1566US2022323483A1Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1663US11331332B2Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitorsREGENERON PHARMA·Filed 2020·Granted May 17, 2022·0 cites·16 claims
- 1763US5766851ASusceptibility gene for obesity and type II diabetes mellitusUNIV JOHNS HOPKINS MED·Filed 1995·Granted Jun 16, 1998·28 cites·21 claims
- 1861US2024207204A1Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) AgonistsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1960US2023000897A1Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) AgentsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2058US11504390B2Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitorsREGENERON PHARMA·Filed 2020·Granted Nov 22, 2022·0 cites·20 claims
- 2157US10738284B2B4GALT1 cDNA variants and compositions comprising the sameREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·0 cites·13 claims
- 2256US12480103B2B4GALT1 variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 25, 2025·0 cites·14 claims
- 2355US2009317393A1Method of modifying glucose activity using polypeptides selectively expressed in fat tissueUNIV MARYLAND·Filed 2007·Application pending·0 cites
- 2455US2022217956A1Rodent Model Of Increased Bone Mineral DensityREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2550US2004234977A1Novel alanine transaminase enzyme and methods of useFiled 2002·Application pending·0 cites
- 2649US2021274759A1A rodent model of b4galt1-mediated functionsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2748US10463716B2Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormoneUNIV MARYLAND·Filed 2015·Granted Nov 5, 2019·0 cites·10 claims
- 2848US2005214883A1Novel alanine transaminase enzyme and methods of useGONG DA-WEI·Filed 2005·Application pending·0 cites
- 2947US2008305485A1Genetic marker for increased risk for obesity-related disordersUNIV MARYLAND·Filed 2008·Application pending·0 cites
- 3046US7914985B2Alanine transaminase enzymes and methods of useUNIV MARYLAND·Filed 2005·Granted Mar 29, 2011·0 cites·5 claims
- 3143US2011033444A1Genetic variants in a hypertension susceptibility gene Stk39 and uses thereofCHANG YEN-PEI·Filed 2010·Application pending·0 cites
- 3236US8058014B2Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2GONG DA-WEI·Filed 2007·Granted Nov 15, 2011·0 cites·6 claims
- 3335US5877283APolypeptide for obesity and type II diabetes mellitusUNIV JOHNS HOPKINS MED·Filed 1998·Granted Mar 2, 1999·2 cites·1 claims
- 3429US2009280108A1Serum amyloid a protein in inflammation and obesityGONG DA-WEI·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alan Shuldiner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →